Figure 3.

ACR50. The results for the NMA on ACR50 at week 16. (A) b/tsDMARD-naïve patients including forest plot and SUCRA values. FE baseline–adjusted model DIC = 469.59. (B) TNFi-experienced patients including forest plot and SUCRA values. RE-unadjusted model DIC = 205.33. ^aWeek 24 data were used as week 16 data was not available. ^*The 95% CrI does not include 1; bimekizumab 160 mg Q4W is considered either better or worse depending on the direction of the effect. ABA: abatacept; ADA: adalimumab; APR: apremilast; b/tsDMARD-naïve: biologic and targeted synthetic DMARD-naïve; BKZ: bimekizumab; CrI: credible interval; CZP: certolizumab pegol; DIC: deviance information criterion; ETA: etanercept; FE: fixed effects; GOL: golimumab; GUS: guselkumab; IFX: infliximab; IV: intravenous; IXE: ixekizumab; NMA: network meta-analysis; PBO: placebo; Q4W: every 4 weeks; Q8W: every 8 weeks; RE: random effects; RIS: risankizumab; SEC: secukinumab; SUCRA: surface under the cumulative ranking curve; TNFi-experienced: TNF inhibitor–experienced; TOF: tofacitinib; UPA: upadacitinib; UST: ustekinumab; w/o LD: without loading dose